Masu hikimar magana na cewa “tafiya sannu a hankali ba ta hana isa inda aka dosa”. Yayin da kasashen duniya ke ci gaba da fafutukar yadda za a fidda jaki daga duma wajen mallakar riga-kafin cutar numfashi ta COVOD-19 wacce ke cigaba da addabar duniya a halin yanzu, hankalin duniya ya fi karkata ne wajen neman mallakar riga-kafin annobar wanda masana ke ganin shi ne kadai mafita a kokarin da ake na yaki da cutar a duniya. Wani labari mai faranta rai shi ne, a karshen makon jiya ne hukumar lafiya ta duniya WHO, ta sanar da cewa, allurar rigakafin cutar COVID-19 na kamfanin Sinopharm na kasar Sin, ya samu sahhalewar hukumar don yin amfani da shi a matakin gaggawa, hakan ya sa allurar Sinopharm ta zama irinta ta 6 da ta samu izinin WHO, kuma allura daya tilo ta kasar da ba ta yammacin duniya ba. Shugaban hukumar Tedros Adhanom Ghebreyesus ya bayyana yayin wani taron manema labarai cewa, wannan mataki zai taimaka wajen habaka samar da allurar da kuma samun nasarar shirin yarjejeniyar raba alluran na COVAX a duniya, kuma zai karfafa gwiwar kasashen duniya wajen gaggauta amincewa da allurar don amfani da ita a kasashensu. Ko shakka babu, wannan labarin ya yi matukar jan hankalin kasa da kasa, kuma hakan ne ya sa tun bayan da rahoto ya bayyana cewa alluran riga-kafin cutar numfashi ta COVID-19 na kamfanin Sinopharm na Sin ya samu takardar shaidar amfanin gaggawa daga hukumar WHO, jami'ai da kwararrun kasashen Afirka da dama sun yi maraba da wannan mataki, inda suka bayyana shi da cewa babbar nasara ce ga duniya baki daya.

Ahmed Ogwell, mataimakin Daraktan Cibiyar kula da rigakafin cututtuka ta Afirka, ya fada a wata hirar da kamfanin dillancin labarai na Xinhua cewa, alluran riga-kafin na Sinopharm na kasar Sin sun samu tabbaci daga hukumar WHO don yin amfani da shi cikin gaggawa, wanda ya kasance labari ne mai kyau ga kasashe da jama’ar da annobar ta addaba, kuma an bayar da wata dama ce ta yin zabi ga shirin aiwatar da allurar rigakafin COVID-19 na COVAX wanda hukumar WHO ke jagoranta da kuma kasashen da ke fama da karancin allurar rigakafin. Ya kara da cewa, cibiyar kula da rigakafin cututtuka ta Afirka za ta ci gaba da hada kai tare da masu samar da allurar rigakafin, ciki har da Sinopharm, don tabbatar da cewa Afirka za ta iya samun alluran riga-kafi masu inganci da amfani da kuma araha, hakan za a iya cimma burin yin rigakafin ga ’yan Afirka a kalla da kashi 60 bisa 100. Koda yake, ba wai mista Ogwell ne kadai ke da wannan ra’ayi ba, shi ma ministan kiwon lafiya na kasar Zambiya Jonas Kamima Chanda ya bayyana cewa, a halin yanzu an riga an tabbatar da riga-kafin Sinopharm ya zama riga-kafi mai amfani da inganci. Gwamnatin kasarsa za ta yi la’akari da shigar da alluran riga-kafin Sinopharm, don tabbatar da yiwa mutane mafi yawa allurar rigakafin. Hakika wannan matakin babbar nasara ce ga shirin yaki da annobar wacce har yanzu ke kara ta’azzara a kasashen duniya. (Ahmad)